Meaningful positive changes in fundamentals have recently occurred for Catalyst Pharmaceutical Inc (NASDAQ: CPRX): the consensus estimate for December, 2026 increased significantly, the consensus estimate for December, 2025 increased significantly, and significant quarterly earnings acceleration occurred.
Significant positive changes in investment behavior have recently occurred for Catalyst Pharmaceutical Inc (NASDAQ: CPRX): the stock rose on very heavy volume.
In light of these very positive signals we are reviewing our current Overall Rating of C. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
Catalyst Pharmaceutical has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Catalyst Pharmaceutical has a very high Appreciation Score of 94 but a poor Power Rating of 27, resulting in the High Neutral Value Trend Rating.
Recent Price Action
Catalyst Pharmaceutical Inc (NASDAQ: CPRX) stock closed at $20.91 on 10/1/25 after a very large increase of 6.1%. Moreover, this advance was accompanied by exceptionally high trading volume at 315% of normal. The stock has been weak relative to the market over the last nine months but has risen 5.7% during the last week.
Be the first to comment